David Kronn

1.9k total citations
35 papers, 1.0k citations indexed

About

David Kronn is a scholar working on Physiology, Rheumatology and Clinical Biochemistry. According to data from OpenAlex, David Kronn has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 13 papers in Rheumatology and 7 papers in Clinical Biochemistry. Recurrent topics in David Kronn's work include Lysosomal Storage Disorders Research (17 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Metabolism and Genetic Disorders (7 papers). David Kronn is often cited by papers focused on Lysosomal Storage Disorders Research (17 papers), Glycogen Storage Diseases and Myoclonus (9 papers) and Metabolism and Genetic Disorders (7 papers). David Kronn collaborates with scholars based in United States, United Kingdom and Japan. David Kronn's co-authors include Mia MacCollin, M. Priscilla Short, Somasundaram Jayabose, Claudio Sandoval, James I. Geller, James F. Gusella, Kevin Davis, Lee B. Jacoby, Valerie Jansen and Harry Ostrer and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Neuroscience & Biobehavioral Reviews.

In The Last Decade

David Kronn

34 papers receiving 987 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Kronn United States 15 362 284 274 270 195 35 1.0k
Carolina Fischinger Moura de Souza Brazil 19 507 1.4× 81 0.3× 279 1.0× 183 0.7× 170 0.9× 110 1.2k
Parayil Sankaran Bindu India 19 386 1.1× 262 0.9× 108 0.4× 80 0.3× 61 0.3× 92 1.1k
Nicole Muschol Germany 23 291 0.8× 70 0.2× 228 0.8× 102 0.4× 297 1.5× 93 1.3k
Catherine DeVile United Kingdom 17 274 0.8× 154 0.5× 97 0.4× 224 0.8× 143 0.7× 36 1.1k
Aditi I Dagli United States 8 286 0.8× 51 0.2× 304 1.1× 432 1.6× 70 0.4× 9 762
Argirios Dinopoulos Greece 14 410 1.1× 153 0.5× 40 0.1× 111 0.4× 65 0.3× 43 998
Martin G. Bialer United States 18 547 1.5× 37 0.1× 103 0.4× 472 1.7× 104 0.5× 34 1.3k
Jiddeke M. van de Kamp Netherlands 15 222 0.6× 29 0.1× 94 0.3× 196 0.7× 70 0.4× 24 786
Ting‐Rong Hsu Taiwan 16 201 0.6× 89 0.3× 178 0.6× 40 0.1× 217 1.1× 53 780
Caroline Sevin France 20 551 1.5× 114 0.4× 36 0.1× 268 1.0× 202 1.0× 54 1.4k

Countries citing papers authored by David Kronn

Since Specialization
Citations

This map shows the geographic impact of David Kronn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kronn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kronn more than expected).

Fields of papers citing papers by David Kronn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kronn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kronn. The network helps show where David Kronn may publish in the future.

Co-authorship network of co-authors of David Kronn

This figure shows the co-authorship network connecting the top 25 collaborators of David Kronn. A scholar is included among the top collaborators of David Kronn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kronn. David Kronn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kronn, David, et al.. (2023). P687: State of play: The current landscape of newborn screening for Pompe disease in the United States. SHILAP Revista de lepidopterología. 1(1). 100759–100759. 2 indexed citations
3.
Kishnani, Priya S., David Kronn, Shugo Suwazono, et al.. (2023). Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry. Orphanet Journal of Rare Diseases. 18(1). 381–381. 6 indexed citations
4.
Kishnani, Priya S., David Kronn, Anaïs Brassier, et al.. (2022). Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. Genetics in Medicine. 25(2). 100328–100328. 28 indexed citations
5.
Duong, Tina, Priya S. Kishnani, Kristina An Haack, et al.. (2022). Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort. Journal of Neuromuscular Diseases. 9(6). 713–730. 3 indexed citations
6.
7.
Shah, Nehal, Frank Birklein, Seward B. Rutkove, et al.. (2021). Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases. Neuroscience & Biobehavioral Reviews. 124. 267–290. 28 indexed citations
8.
Byrne, Barry J., Steven D. Colan, Priya S. Kishnani, et al.. (2021). Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort. Cardiology in the Young. 32(3). 364–373. 6 indexed citations
9.
Conte, Federica, Éva Morava, Nurulamin Abu Bakar, et al.. (2020). Phosphoglucomutase-1 deficiency: Early presentation, metabolic management and detection in neonatal blood spots. Molecular Genetics and Metabolism. 131(1-2). 135–146. 19 indexed citations
10.
Kishnani, Priya S., James B. Gibson, Michael J. Gambello, et al.. (2019). Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease. Genetics in Medicine. 21(11). 2543–2551. 9 indexed citations
11.
12.
Kazi, Zoheb B., Ankit K. Desai, Kathryn L. Berrier, et al.. (2017). Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2(16). 47 indexed citations
13.
Vogel, Beth, Darius J. Adams, Kristin D׳Aco, et al.. (2015). Newborn screening for X-linked adrenoleukodystrophy in New York State: Diagnostic protocol, surveillance protocol and treatment guidelines. Molecular Genetics and Metabolism. 114(4). 599–603. 84 indexed citations
14.
Kronn, David, Shideh Mofidi, Nancy Braverman, & Katharine B. Harris. (2010). Diagnostic guidelines for newborns who screen positive in newborn screening. Genetics in Medicine. 12(12 Suppl). S251–S255. 8 indexed citations
15.
Arnold, Georgianne L., Carlos A. Saavedra‐Matiz, Patricia Galvin‐Parton, et al.. (2009). Lack of genotype–phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Molecular Genetics and Metabolism. 99(3). 263–268. 48 indexed citations
16.
Sandoval, Claudio, Sharon R. Pine, Qianxu Guo, et al.. (2004). Tetrasomy 21 transient leukemia with aGATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: Case report and review of the literature. Pediatric Blood & Cancer. 44(1). 85–91. 18 indexed citations
17.
Geller, James I., David Kronn, Somasundaram Jayabose, & Claudio Sandoval. (2002). Hereditary Folate Malabsorption. Medicine. 81(1). 51–68. 95 indexed citations
18.
Kronn, David, Valerie Jansen, & Harry Ostrer. (1998). Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population. Archives of Internal Medicine. 158(7). 777–777. 47 indexed citations
19.
Jacoby, Lee B., Kevin Davis, David Kronn, et al.. (1997). Molecular Analysis of the NF2 Tumor-Suppressor Gene in Schwannomatosis. The American Journal of Human Genetics. 61(6). 1293–1302. 122 indexed citations
20.
MacCollin, Mia, et al.. (1996). Schwannomatosis. Neurology. 46(4). 1072–1079. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolina Fischinger Moura de Souza Breakdown of academic impact, for papers by Parayil Sankaran Bindu Breakdown of academic impact, for papers by Nicole Muschol Breakdown of academic impact, for papers by Catherine DeVile Breakdown of academic impact, for papers by Aditi I Dagli Breakdown of academic impact, for papers by Argirios Dinopoulos Breakdown of academic impact, for papers by Martin G. Bialer Breakdown of academic impact, for papers by Jiddeke M. van de Kamp Breakdown of academic impact, for papers by Ting‐Rong Hsu Breakdown of academic impact, for papers by Caroline Sevin
Rankless by CCL
2026